Barclays lowered the firm’s price target on Roche to CHF 250 from CHF 260 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Roche sees FY24 core EPS up broadly in line with sales growth
- Roche reports FY23 group sales CHF 58.7B, up 1% y/y
- Genentech announces new 72-week data from BALATON, COMINO studies
- [Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
- New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)